Replimune Group, Inc.
REPLDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Jun 25, 2026
4dMarket Overview
Stock performance and key metrics
3 upcoming, 3 past
REPL Earnings Report
EPS Est: $-0.73 | FQ end 2026-03
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Vusolimogene Oderparepvec
Advanced Melanoma
RP2
Metastatic Uveal Melanoma
RP1
Non-Small Cell Lung Cancer (NSCLC)
RP3
Refractory Metastatic Colorectal Cancer
Cemiplimab
Cutaneous Squamous Cell Carcinoma
RP1, intra-tumoral injection, oncolytic virus
Cutaneous Squamous Cell Carcinoma
RP2 Monotherapy
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vusolimogene Oderparepvec | Phase 3 | Advanced Melanoma | - | - |
RP2 | Phase 3 | Metastatic Uveal Melanoma | - | - |
RP1 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
RP3 | Phase 2 | Refractory Metastatic Colorectal Cancer | - | - |
Cemiplimab | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
RP1, intra-tumoral injection, oncolytic virus | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
RP2 Monotherapy | Phase 2 | Hepatocellular Carcinoma | - | - |